Dipeptidyl peptidase-4 and kidney fibrosis in diabetes [PDF]
, 2016 Daisuke Koya, Keizo Kanasaki, Sen Shi
core +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.ABSTRACT The high prevalence of gastrointestinal (GI) diseases and their significant impact on the quality of life require new therapeutic strategies. The development of novel therapeutic strategies should prioritize targeting the fundamental pathophysiological mechanisms underlying these diseases, including inflammation, cellular proliferation, and ...
Sayedeh Azimeh Hosseini +7 more
wiley +1 more source
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
Vascular Health and Risk Management, 2007 Baptist GallwitzDept. Medicine IV, Eberhard Karls University, Tuebingen, GermanyAbstract: Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 ...
Baptist Gallwitz
doaj
Diabetic Medicine, Volume 43, Issue 6, June 2026.Abstract Introduction and Objectives Inpatient hypoglycaemia is a serious complication of diabetes therapy, yet real‐world data on clinically significant episodes remain limited. The objectives of this study are (1) to describe the clinical and biochemical characteristics of clinically significant inpatient hypoglycaemia across multiple NHS sites, (2 ...
Charles Page +16 more
wiley +1 more source
Meat Proteins as Dipeptidyl Peptidase IV Inhibitors and Glucose Uptake Stimulating Peptides for the Management of a Type 2 Diabetes Mellitus In Silico Study. [PDF]
Nutrients, 2019 Kęska P, Stadnik J, Bąk O, Borowski P.
europepmc +1 more source
Obstructive sleep apnoea is associated with accelerated progression of diabetic kidney disease
Diabetic Medicine, Volume 43, Issue 6, June 2026.Abstract Aim Persons with type 2 diabetes and diabetic kidney disease (DKD) are at high risk of end‐stage kidney disease or death. We investigated the possible contribution of obstructive sleep apnoea (OSA) to decline in kidney function and renal outcomes.
Sebastian Nielsen +9 more
wiley +1 more source
A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors. [PDF]
Front Immunol, 2019 Izumi K, Nishie W, Beniko M, Shimizu H.
europepmc +1 more source
Dementia Risk in Type 1 and 2 Diabetes: A Nationwide Population‐Based Comparison
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4915-4925, June 2026.ABSTRACT Aims Diabetes is increasingly recognised as a major contributor to cognitive decline and dementia, but the risk varies by diabetes type and treatment intensity. We compared the risk of all‐cause dementia, Alzheimer's disease (AD) and vascular dementia (VaD) among individuals with and without diabetes.
Ji Eun Jun +3 more
wiley +1 more source
Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study. [PDF]
J Clin Med, 2018 Kim YG +6 more
europepmc +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5058-5067, June 2026.ABSTRACT Aims The REALISED study assessed the clinical outcomes associated with oral semaglutide use in Thai patients with type 2 diabetes (T2D) in real‐world clinical settings. Materials and Methods This retrospective, multi‐centre cohort study included 195 patients with T2D initiating oral semaglutide between April 2022 and December 2023.
Taweesak Wannachalee +6 more
wiley +1 more source